Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
876 results about "Disease causative agent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The term disease causative agent usually refers to the biological pathogen that causes a disease, such as a virus, parasite, fungus, or bacterium. Technically, the term can also refer to a toxin or toxic chemical that causes illness.
Methods for sterilizing biological materials by irradiation over a temperature gradient
InactiveUS6908591B2Effective sterilizationImprove permeabilityDead animal preservationLavatory sanitoryBiological materialsBiology
Methods are disclosed for sterilizing tissue to reduce the level of one or more active biological contaminants or pathogens therein, such as viruses, bacteria, (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), yeasts, molds, fungi, spores, prions or similar agents responsible, alone or in combination, for TSEs and / or single or multicellular parasites. The methods involve sterilizing one or more tissues with irradiation.
Owner:CLEARANT
Integrated health data capture and analysis system
ActiveUS20110093249A1Mitigate spreadReduce transmissionMedical simulationMedical data miningOutbreakChronic disease
The present invention provides an integrated health care surveillance and monitoring system that provides real-time sampling, modeling, analysis, and recommended interventions. The system can be used to monitor infectious and chronic diseases. When faced with outbreak of an infectious disease agent, e.g., influenza virus, the system can identify active cases through pro-active sampling in high risk locations, such as schools or crowded commercial areas. The system can notify appropriate entities, e.g., local, regional and national governments, when an event is detected, thereby allowing for proactive management of a possible outbreak. The system also predicts the best response for deployment of scarce resources.
Owner:LABRADOR DIAGNOSTICS LLC
Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
InactiveUS20070053849A1Potent anti-inflammatory activityPromote progressAntibacterial agentsCosmetic preparationsWhole bodyOral bacterial infection
The present invention encompasses topical oral care compositions comprising the combination of an anti-bacterial agent with an anti-inflammatory agent in an orally acceptable carrier for effective treatment and prevention of bacteria-mediated diseases and conditions in the oral cavity and for modulating host reaction to bacterial pathogens present in the oral cavity and to the toxins, endotoxins, inflammatory cytokines and mediators released by or prompted by these pathogens. The present invention also encompasses methods of use of these compositions comprising topical application to the oral cavity. The benefits of the present compositions and methods extend beyond treating and preventing oral bacterial infections in the oral cavity to promoting whole body or systemic health.
Owner:THE PROCTER & GAMBLE COMPANY
Pharmaceutical compositions and treatment methods
InactiveUS6667299B1Efficient transportReduce yieldAntibacterial agentsOrganic active ingredientsRegimenKetone
The invention provides compositions comprising, 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Owner:NEURMEDIX +2
Process to study changes in gene expression in granulocytic cells
InactiveUS6365352B1Resistant to digestionDigestion of every cDNA is assuredMicrobiological testing/measurementBacteroidesNeutrophil granulocyte
The present invention comprises a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen or in a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen or isolated from a subject having a sterile inflammatory disease and comparing that profile to a profile prepared from quiescent granulocytic cells. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules. The invention also includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a granulocytic population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.
Owner:YALE UNIV +2
Compositions and methods for administering Borrelia DNA
Disclosed is a vaccine against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion / release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion / release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.
Owner:PASTEUR MERIEUX SERUMS & VACCINS SA
Nitric oxide gas (gO) as a cosmetic and wound healing agent
InactiveUS20070065473A1Reducing size and duration and severityPromote healingCosmetic preparationsHair removalMammalian tissueEngineering
The present invention provides a method and device for exposing injured mammalian tissues, in a non-abrasive manner, to an effective amount of exogenous gaseous nitric oxide (gNO) in order to promote healing by reducing the size, duration and severity of wounds as well as controlling the infection by reducing number of pathogens at the site and the surrounding area. The present invention also provides methods of cosmetically treating the skin wherein a cosmetic agent in combination with gNO is applied to the skin.
Owner:PULMONOX TECH
Method for producing immunoglobulins containing protection proteins in plants and their use
The immunoglobulins of the present invention are useful therapeutic immunoglobulins against mucosal pathogens such as S. mutans. The immunoglobulins contain a protection protein that protects the immunoglobulins in the mucosal environment.The invention also includes the greatly improved method of producing immunoglobulins in plants by producing the protection protein in the same cell as the other components of the immunoglobulins. The components of the immunoglobulin are assembled at a much improved efficiency. The method of the invention allows the assembly and high efficiency production of such complex molecules.The invention also contemplates the production of immunoglobulins containing protection proteins in a variety of cells, including plant cells, that can be selected for useful additional properties. The use of immunoglobulins containing protection proteins as therapeutic antibodies against mucosal and other pathogens is also contemplated.
Owner:UNTD MED & DENT SCHLS OF GUYS & ST THOMASS HOSP
Pharmaceutical compositions of rifaximin
ActiveUS20090028940A1Extended stayImprove complianceAntibacterial agentsBiocideImmediate releasePharmaceutical medicine
A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.
Owner:LUPIN LTD
Antifungal polypeptides
Owner:RGT UNIV OF CALIFORNIA +2
Magnetic nanoscale particle compositions, and therapeutic methods related thereto
InactiveUS20060142749A1Minimal invasionShort course of treatmentAntibacterial agentsPowder deliveryDiseaseMagnetite Nanoparticles
Disclosed are thermotherapeutic compositions for treating disease material, and methods of targeted therapy utilizing such compositions. These compositions comprise a) stable single domain magnetic particles; b) magnetic nanoparticles comprising aggregates of superparamagnetic grains; or c) magnetic nanoparticles comprising aggregates of stable single magnetic domain crystals and superparamagnetic grains. These compositions may also comprise a radio isotope, potential radioactive isotope, chemotherapeutic agent. These methods comprise the administration to a patient's body, body part, body fluid, or tissue of bioprobes (energy susceptive materials attached to a target-specific ligand), and the application of energy to the bioprobes so as to destroy, rupture, or inactivate the target in the patient. Energy forms, such as AMF, are utilized to provide the energy. The disclosed methods may be useful in the treatment of a variety of indications, including cancers, diseases of the immune system, central nervous system and vascular system, and pathogen-borne diseases.
Owner:ASPEN MEDISYS +1
Immunogenic compositions and uses thereof
ActiveUS20140242152A1Enhance immune responseSsRNA viruses negative-sensePowder deliveryEpitopeImmunogenicity
This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form—are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA-based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Biotic and abiotic stress tolerance in plants
InactiveUS20090138981A1Improve the immunityIncreased susceptibilityBryophytesSugar derivativesBiotechnologyNucleotide
Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress). The abiotic stress may include, for example, salt, hyperosmotic stress, water deficit, heat, cold, drought, or low nutrient conditions.
Owner:MENDEL BIOTECHNOLOGY INC
Biocidal compositions for treating water
InactiveUS6093422AEffective destructionEfficient Growth InhibitionOrganic active ingredientsBiocideCrosslinked chitosanSulfate zinc
The present invention is directed to a biocidal water treatment composition, water treatment apparatus, and method of treating water to reduce levels of pathogens. The composition contains sources of copper, zinc, and silver metal ions within a crosslinked polymer matrix. Examples of these ion sources include copper sulfate, zinc sulfate, and silver nitrate. An example of the crosslinked polymer matrix is crosslinked chitosan, which also serves to clarify the water and release the metal ions over time. The product is easy to manufacture, and allows the use of decreased halogen sanitizer, as well as decreased copper ion, thereby decreasing the likelihood of staining. The product simultaneously provides good bactericidal and algaecidal properties, despite low levels of copper ion and low chlorine levels.
Owner:ZODIAC POOL SYST
Pathogen inactivating compositions for disinfecting biological fluids
InactiveUS6106773AAvoid bulk processingAvoid capital intensive equipmentBiocideSolvent extractionBlood componentAqueous solution
The present invention is directed to pathogen inactivating compositions that can be used to disinfect various biological fluids, such as blood, blood fractions, and the like. The compositions are suitable for disinfecting biological fluids containing valuable, but labile, components such as proteins without destroying the desired properties of such components. The pathogen inactivating compositions of the present invention are produced by contacting water or an aqueous solution with iodinated matrix material. The compositions can be pre-formulated and stored for subsequent use in disinfecting a wide range of biological fluids.
Owner:AMERICAN NAT RED CROSS
Polymeric anti-microbial agents
InactiveUS20070231291A1Low toxicitySubstantial and broad spectrum reduction in microorganism populations quicklyOrganic active ingredientsBiocideMicrobial agentHuman toxicity
Polymeric anti-microbial agents produced by substituting the nitrogen atoms in the backbone of ethylenimine polymers are provided. The agents are believed to have low human toxicity while being effective against a variety of pathogens and are useful in applications involving human contact, such as cosmetics, hair care products and textiles, as well as in applications with much less human contact, such as coatings.
Owner:CIBA SPECIALTY CHEM CORP
Anti-pathogenic air filtration media and air handling devices having protective capabilities against infectious airborne mircoorganisms
The present invention provides an anti-pathogenic air filtration medium comprising a fibrous substrate whose fibers are coated with coating comprising a polymer. The coating provides an environment that is destructive to airborne pathogens. In particular, the filter medium can be used in a building air handling system that both filters the air and eliminates pathogens. The filter medium also can be used to create a new bio-protective gas mask that not only offers protection against chemical warfare agents, but also provides protection against biological pathogens.
Owner:INNOVATIVE CONSTR & BUILDING MATERIALS
Biocidal polyurethane compositions and methods of use
InactiveUS7459167B1Improve adhesionImprove hydrolytic resistanceOrganic active ingredientsBiocideMicroorganismAmmonium compounds
Polymeric compositions that include polyurethane polymers derived from a polyisocyanate compound and a polyactive hydrogen compound. The polyurethane compound is at least partially endcapped with a group including at least one antimicrobial quaternary ammonium compound. The polymeric composition of the present invention is capable of forming a self-supporting film. The polymeric compositions are suitable for coating substrates to effectively kill or prevent the growth of microorganisms such as bacteria, mold, mildew, algae fungi and the like. The polymeric compositions are particularly useful for protecting construction materials used in moist, outdoor environments to prevent discoloration or decay from microorganisms and for surfaces in health care facilities to mitigate the spread of pathogens.
Owner:3M INNOVATIVE PROPERTIES CO
Indole compounds as COX-2 inhibitors
InactiveUS6300363B1Inhibit prostaniod-induced smooth muscle contractionInhibit synthesisBiocideOrganic chemistryDiseaseEthyl group
This invention provides a compound of the following formula:and the pharmaceutically acceptable salts thereof, wherein L is oxygen or sulfur; Y is a direct bond or C1-4 alkylidene; Q is C1-6 alkyl, C3-7 cycloalkyl, phenyl, naphthyl, heteroaryl or the like; R1 is hydrogen, C1-6 alkyl or the like; R2 is hydrogen, C1-4 alkyl, C(O)R5 wherein R5 is C1-22 alkyl or C2-22 alkenyl, halosubstituted C1-8 alkyl, halosubstituted C2-8alkenyl, -Y-C3-7 cycloalkyl, -Y-C3-7 cycloalkenyl, phenyl, naphthyl, heteroaryl or the like; X is halo, C1-4 alkyl, hydroxy, C1-4 alkoxy or the like; and n is 0, 1, 2 or 3, with the proviso that a group of formula -Y-Q is not methyl or ethyl when X is hydrogen; L is oxygen; R1 is hydrogen; and R2 is acetyl.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
Owner:PFIZER INC +1
Antifungal polypeptides
Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include an amino acid sequence, and variants and fragments thereof, for an antipathogenic polypeptide that was isolated from a fungal fermentation broth. Nucleic acid molecules that encode the antipathogenic polypeptides of the invention, and antipathogenic domains thereof, are also provided. A method for inducing pathogen resistance in a plant using the nucleotide sequences disclosed herein is further provided. The method comprises introducing into a plant an expression cassette comprising a promoter operably linked to a nucleotide sequence that encodes an antipathogenic polypeptide of the invention. Compositions comprising an antipathogenic polypeptide or a transformed microorganism comprising a nucleic acid of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Transformed plants, plant cells, seeds, and microorganisms comprising a nucleotide sequence that encodes an antipathogenic polypeptide of the invention are also disclosed.
Owner:PIONEER HI BRED INT INC +2
Broad spectrum anti-viral therapeutics and prophylaxis
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of the target cell by a pathogen, such as a virus. Preferred target cells are epithelial cells. The invention provides compositions and methods for preventing viral diseases, such as influenza, using compounds having anchoring domains that can bind target cells linked to enzymatic activities that can act extracellularly to interfere with viral infection of target cells. The invention also provides compositions and methods for preventing viral diseases such as influenza using compounds having anchoring domains that can bind target cells linked to protease inhibitors that can act extracellularly to interfere with viral infection of target cells.
Owner:ANSUN BIOPHARMA
Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
This invention provides a compound of the following formula:or the pharmaceutically acceptable salts thereof wherein A is C 1-6 alkylene or -NR1-; Z is C(=L)R2, or SO2R3; U is CH or N; W and Y are independently selected from -CH2-, O, S and -N-R1; m is 1, 2 or 3; q and r are independently 0, 1 or 2; X is independently selected from halogen, C1-4 alkyl, halo-substituted C1-4 alkyl, hydroxy, C1-4 alkoxy, halo-substituted C1-4 alkoxy or the like; n is 1 or 2; L is oxygen or sulfur; R1 is hydrogen or C1-4 alkyl; R2 is hydroxy, C1-6alkyl, halo-substituted C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C3-7 cycloalkoxy, C1-4 alkyl(C3-7 cycloalkoxy), -NR4R5 or the like; R3 is C1-6 alkyl or halo-substituted C1-6 alkyl; and R4 and R5 are independently selected from hydrogen, C1-6 alkyl and halo-substituted C1-6alkyl.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
Owner:PFIZER INC
Non-thermal disinfection of biological fluids using non-thermal plasma
A method and apparatus are provided for at least partially disinfecting biological fluid of a mammal, which comprises pathogens in addition to normal cellular fractions. The method includes placing the biological fluid in a reaction volume and contacting a non-thermal plasma with the biological fluid to thereby kill at least a portion of the pathogens within the biological fluid.
Owner:RGT UNIV OF MINNESOTA
Stress tolerance in plants
Transcription factor polynucleotides and polypeptides incorporated into nucleic acid constructs, including expression vectors, have been introduced into plants and were ectopically expressed. Transgenic plants transformed with many of these constructs have been shown to be more resistant to disease (in some cases, to more than one pathogen), or more tolerant to an abiotic stress (in some cases, to more than one abiotic stress). The abiotic stress may include, for example, salt, hyperosmotic stress, water deficit, heat, cold, drought, or low nutrient conditions.
Owner:MENDEL BIOTECHNOLOGY INC
Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
ActiveUS20140012097A1Rapid adsorption kineticsMinimizes inflammationBioreactor/fermenter combinationsBiological substance pretreatmentsPathogenRemove blood
The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and / or toxins and / or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and / or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.
Owner:EXTHERA MEDICAL
Biocidal compositions for treating water
InactiveUS6217780B1Effective destruction and growth inhibitionHigh degreeBiocideDead animal preservationCrosslinked chitosanStaining
Owner:ZODIAC POOL SYST
Absorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
InactiveUS20050142542A1Reduce risk of leakageEasy to manufactureImmobilised enzymesOther blood circulation devicesWhole blood productSorbent
Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix. The matrix containing the particles is contained in a housing, and the particles range in diameter from about 1 μm to about 200 μm. The matrix can be fibrous, and the particles can have a surface area greater than 750 m2 / g and a pore diameter between about 25 and 800 Å. The device can be used to adsorb and remove a pathogen-inactivating compound that is a nucleic acid-binding compound such as psoralen, an acridine derivative or a dye from a biological composition such as a blood product.
Owner:CERUS CORP
Recombinant avipox virus
The present invention provides a method for inducing an immunological response in a vertebrate to a pathogen by inoculating the vertebrate with a synthetic recombinant avipox virus modified by the presence, in a non-essential region of the avipox genome, of DNA from any source which encodes for and expresses an antigen of the pathogen. The present invention further provides a synthetic recombinant avipox virus modified by the insertion therein of DNA from any source, and particularly from a non-avipox source, into a non-essential region of the avipox genome.
Owner:HEALTH RES INC
Bacterial efflux pump inhibitors and methods of treating bacterial infections
InactiveUS20060003944A1Reduce and eliminate tissue damageAvoid bacterial infectionAntibacterial agentsBiocideMedicineTreatment use
This invention relates to the field of antimicrobial agents and more specifically it relates to Efflux Pump Inhibitor (EPI) compounds to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens. The EPI compounds are soft drugs which exhibit a reduced propensity for tissue accumulation. The invention includes novel compounds useful as efflux pump inhibitors, compositions and devices comprising such efflux pump inhibitors, and therapeutic use of such compounds.
Owner:REMPEX PHARM INC
Immunogenic compositions and uses thereof
PendingUS20210290755A1Enhance immune responseSsRNA viruses negative-senseSsRNA viruses positive-senseEpitopeMicrobiology
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com